

## **Galmed Pharmaceuticals to Present at the 27th Annual ROTH Conference**

TEL AVIV, Israel, March 2, 2015 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed"), a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones, today announced that Josh Blacher, Chief Financial Officer, will present a company overview at the 27th Annual ROTH conference in Laguna Niguel, California on Monday, March 9, 2015 at 2:30 PM Pacific Standard Time. A live webcast of the presentation will be available at <http://galmedpharma.investorroom.com/>.

### **About Galmed Pharmaceuticals Ltd.**

Galmed is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel, once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its proprietary first-in-class family of synthetic fatty-acid/bile-acid conjugates, or FABACs. Galmed believes that its product candidate, aramchol, has the potential to be a disease modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-Hepatitis, which is a chronic disease that Galmed believes constitutes a large unmet medical need.

### **Forward-Looking Statements**

*This press release includes forward-looking statements. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Applicable risks and uncertainties include those identified under the heading "Risk Factors" included in the registration statement on Form F-1 (File No. 333 -193792), initially filed with the Securities and Exchange Commission, or the SEC, on February 6, 2014 and declared effective by the SEC on March 12, 2014, and in other filings that Galmed has made and may make with the SEC in the future. The forward-looking statements contained in this press release reflect Galmed's current views with respect to future events, and Galmed does not undertake and specifically disclaims any obligation to update any forward-looking statements.*

To view the original version on PR Newswire, visit <http://www.prnewswire.com/news-releases/galmed-pharmaceuticals-to-present-at-the-27th-annual-roth-conference-300043426.html>

SOURCE Galmed Pharmaceuticals Ltd.

For further information: Investor Contact: Josh Blacher, CFO, Galmed Pharmaceuticals Ltd.,

josh@galmedpharma.com, +1-646-780-7605

---

<https://galmedpharma.investorroom.com/2015-03-02-Galmed-Pharmaceuticals-to-Present-at-the-27th-Annual-ROTH-Conference,1>